Fostemsavir continues to BRIGHTEn outlook for advanced HIV-1 patients
17 Aug 2021
byAudrey Abella
In the 96-week interim analysis of the phase III BRIGHTE study presented at IAS 2021, the gp120 attachment inhibitor fostemsavir showed favourable safety and tolerability, and yielded strong rates of virologic response in heavily treatment-experienced (HTE) adults infected with extensive multidrug-resistant (MDR) HIV-1.